These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21157296)

  • 1. Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapy.
    Goodman DD; Zhou Y; Margot NA; McColl DJ; Zhong L; Borroto-Esoda K; Miller MD; Svarovskaia ES
    AIDS; 2011 Jan; 25(3):325-33. PubMed ID: 21157296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of HIV-1 drug resistance through 144 weeks in antiretroviral-naïve subjects on emtricitabine, tenofovir disoproxil fumarate, and efavirenz compared with lamivudine/zidovudine and efavirenz in study GS-01-934.
    Margot NA; Enejosa J; Cheng AK; Miller MD; McColl DJ;
    J Acquir Immune Defic Syndr; 2009 Oct; 52(2):209-21. PubMed ID: 19644384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
    Marcelin AG; Charpentier C; Wirden M; Landman R; Valantin MA; Simon A; Katlama C; Yeni P; Descamps D; Aubron-Olivier C; Calvez V
    J Antimicrob Chemother; 2012 Jun; 67(6):1475-8. PubMed ID: 22371439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV.
    Gallant JE; DeJesus E; Arribas JR; Pozniak AL; Gazzard B; Campo RE; Lu B; McColl D; Chuck S; Enejosa J; Toole JJ; Cheng AK;
    N Engl J Med; 2006 Jan; 354(3):251-60. PubMed ID: 16421366
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term treatment with raltegravir or efavirenz combined with tenofovir/emtricitabine for treatment-naive human immunodeficiency virus-1-infected patients: 156-week results from STARTMRK.
    Rockstroh JK; Lennox JL; Dejesus E; Saag MS; Lazzarin A; Wan H; Walker ML; Xu X; Zhao J; Teppler H; Dinubile MJ; Rodgers AJ; Nguyen BY; Leavitt R; Sklar P;
    Clin Infect Dis; 2011 Oct; 53(8):807-16. PubMed ID: 21921224
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early virological failure with a combination of tenofovir, didanosine and efavirenz.
    Podzamczer D; Ferrer E; Gatell JM; Niubo J; Dalmau D; Leon A; Knobel H; Polo C; Iniguez D; Ruiz I
    Antivir Ther; 2005; 10(1):171-7. PubMed ID: 15751775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modulation of K65R selection by zidovudine inclusion: analysis of HIV resistance selection in subjects with virologic failure receiving once-daily abacavir/lamivudine/zidovudine and tenofovir DF (study COL40263).
    Ross L; Elion R; Lanier R; Dejesus E; Cohen C; Redfield RR; Gathe JC; Hsu RK; Yau L; Paulsen D; Ha B;
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):665-72. PubMed ID: 19563238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minority quasispecies of drug-resistant HIV-1 that lead to early therapy failure in treatment-naive and -adherent patients.
    Metzner KJ; Giulieri SG; Knoepfel SA; Rauch P; Burgisser P; Yerly S; Günthard HF; Cavassini M
    Clin Infect Dis; 2009 Jan; 48(2):239-47. PubMed ID: 19086910
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Impact of switching virologically suppressed, HIV-1-infected patients from twice-daily fixed-dose zidovudine/lamivudine to once-daily fixed-dose tenofovir disoproxil fumarate/emtricitabine.
    DeJesus E; Ruane P; McDonald C; Garcia F; Sharma S; Corales R; Ravishankar J; Khanlou H; Shamblaw D; Ecker J; Ebrahimi R; Flaherty J;
    HIV Clin Trials; 2008; 9(2):103-14. PubMed ID: 18474495
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Resistance development over 144 weeks in treatment-naive patients receiving tenofovir disoproxil fumarate or stavudine with lamivudine and efavirenz in Study 903.
    Margot NA; Lu B; Cheng A; Miller MD;
    HIV Med; 2006 Oct; 7(7):442-50. PubMed ID: 16925730
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensification of a triple-nucleoside regimen with tenofovir or efavirenz in HIV-1-infected patients with virological suppression.
    Gulick RM; Lalama CM; Ribaudo HJ; Shikuma CM; Schackman BR; Schouten J; Squires KE; Koletar SL; Pilcher CD; Reichman RC; Klingman KL; Kuritzkes DR
    AIDS; 2007 Apr; 21(7):813-23. PubMed ID: 17415036
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost-effectiveness of nucleoside reverse transcriptase inhibitor pairs in efavirenz-based regimens for treatment-naïve adults with HIV infection in the United States.
    Brogan AJ; Talbird SE; Cohen C
    Value Health; 2011; 14(5):657-64. PubMed ID: 21839403
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Successful switch to rilpivirine/tenofovir/emtricitabine in HIV-1-infected patients with an isolated K103N mutation acquired during prior nonnucleoside reverse transcriptase inhibitor therapy.
    Rokx C; Verbon A; Rijnders BJ
    HIV Med; 2014 Nov; 15(10):611-4. PubMed ID: 24738660
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
    Fisher M; Moyle GJ; Shahmanesh M; Orkin C; Kingston M; Wilkins E; Ewan J; Liu H; Ebrahimi R; Reilly G;
    J Acquir Immune Defic Syndr; 2009 Aug; 51(5):562-8. PubMed ID: 19561519
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study.
    Post FA; Moyle GJ; Stellbrink HJ; Domingo P; Podzamczer D; Fisher M; Norden AG; Cavassini M; Rieger A; Khuong-Josses MA; Branco T; Pearce HC; Givens N; Vavro C; Lim ML
    J Acquir Immune Defic Syndr; 2010 Sep; 55(1):49-57. PubMed ID: 20431394
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase II study of vicriviroc versus efavirenz (both with zidovudine/lamivudine) in treatment-naive subjects with HIV-1 infection.
    Landovitz RJ; Angel JB; Hoffmann C; Horst H; Opravil M; Long J; Greaves W; Fätkenheuer G
    J Infect Dis; 2008 Oct; 198(8):1113-22. PubMed ID: 18783318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rate of virologic failure and selection of drug resistance mutations using different triple nucleos(t)ide analogue combinations in HIV-infected patients.
    Martín-Carbonero L; Gil P; García-Benayas T; Barreiro P; Blanco F; de Mendoza C; Maida I; González-Lahoz J; Soriano V
    AIDS Res Hum Retroviruses; 2006 Dec; 22(12):1231-5. PubMed ID: 17209764
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Patient-reported outcomes and low-level residual HIV-RNA in adolescents perinatally infected with HIV-1 after switching to one-pill fixed-dose regimen.
    Rosso R; Di Biagio A; Maggiolo F; Nulvesu L; Callegaro AP; Taramasso L; Bruzzone B; Viscoli C
    AIDS Care; 2012; 24(1):54-8. PubMed ID: 21800951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antiretroviral drugs for prevention of mother-to-child transmission: pharmacologic considerations for a public health approach.
    Lamorde M; Schapiro JM; Burger D; Back DJ
    AIDS; 2014 Nov; 28(17):2551-63. PubMed ID: 25574958
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.